Market Access Advancements and Challenges in “Drug-Companion Diagnostic Test” Co-Development in Europe

Journal of Personalized Medicine

Ildar Akhmetov²  Rakshambikai Ramaswamy²  Illias Akhmetov¹  Phani Kishore Thimmaraju² 

[1] Unicorn, POB 91, Zhytomyr 10020, Ukraine; E-Mail:;Phamax Analytics Resources Pvt. Ltd. #19, KMJ Ascend 1st Cross, 17th C Main 5th Block, Koramangala Bangalore 560 095, India; E-Mails:

关键词: Stratified medicine;    companion diagnostics;    market access;    cost-effectiveness;    value addition;   

DOI  :  10.3390/jpm5020213

来源: mdpi

【 摘 要 】

The pharma ecosphere is witnessing a measured transformation from the one-size-fits-all or blockbuster model of drugs to more informed and tailored personalized treatments that facilitate higher safety and efficacy for a relevant sub-population. However, with several breakthroughs still in a nascent stage, market access becomes a crucial factor for commercial success, especially when it comes to co-creating value for pertinent stakeholders. This article highlights diverse issues from stakeholder perspectives in Europe, specifically the ones which require immediate resolution. Furthermore, the article also discusses case studies articulating potential solutions for the issues discussed.

【 授权许可】

CC BY   
© 2015 by the authors; licensee MDPI, Basel, Switzerland.